2 recruiting, 1 completed. 3 Phase 2, 2 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 3 | Recruiting 2, Completed 1 |
| Phase 1 | 2 | Recruiting 2 |
Follow Adenocarcinoma of Colon: new trials by email Literature Review of Adenocarcinoma of Colon trials Research Report on Adenocarcinoma of Colon
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Dual-Target CAR-NK Cells for Biomarker-Selected Advanced Colorectal Cancer EB-DUO-CAR-NK-CEA/GCC (IV) - Colorectal Cancer Metastatic, Adenocarcinoma of Colon | Phase 1 / Phase 2 | Recruiting | Beijing Biotech | 48 | 2026-02-01 | 2026-03-10 |
| PRE-ISPY Phase I/II Oncology Platform Program ALX148, Fam-Trastuzumab Deruxtecan-Nxki, Zanidatamab - HER2-positive Breast Cancer, Metastatic Cancer | Phase 1 / Phase 2 | Recruiting | QuantumLeap Healthcare Collaborative | 280 | 2023-02-15 | 2026-09-30 |
| Study of Individualized Therapies Selection for Patients With Metastatic Colorectal Carcinoma According to the Therapeutic Arm A chemotherapy, arm B chemotherapy - Adenocarcinoma of Colon, Adenocarcinoma of Rectum | Phase 2 | Completed | Centro Nacional de Investigaciones Oncologicas CARLOS III | 29 | 2012-11-01 | 2015-10-09 |
Colonic Neoplasms (3) · Neoplasm Metastasis (2) · Rectal Neoplasms (2) · Adenocarcinoma (1) · Breast Neoplasms (1) · Colorectal Neoplasms (1) · Neoplasm, Residual (1) · Triple Negative Breast Neoplasms (1)
Colonic Diseases (3) · Digestive System Diseases (3) · Digestive System Neoplasms (3) · Gastrointestinal Diseases (3) · Gastrointestinal Neoplasms (3) · Intestinal Diseases (3) · Intestinal Neoplasms (3) · Neoplasms (3) · Neoplasms by Site (3) · Colorectal Neoplasms (2) · Neoplastic Processes (2) · Pathologic Processes (2) · Pathological Conditions, Signs and Symptoms (2) · Rectal Diseases (2) · Breast Diseases (1)
ALX148 (1) · Capecitabine (1) · Cetuximab (1) · Cisplatin (1) · Dasatinib (1) · Docetaxel (1) · Doxorubicin (1) · Erlotinib Hydrochloride (1) · Etoposide (1) · Fluorouracil (1) · Gemcitabine (1) · Irinotecan (1) · Mitomycin (1) · Oxaliplatin (1) · Paclitaxel (1)
Beijing Biotech (1) · Centro Nacional de Investigaciones Oncologicas CARLOS III (1) · QuantumLeap Healthcare Collaborative (1)
China (1) · Spain (1) · United States (1)